Skip to main content
Article thumbnail
Location of Repository

Tumor Necrosis Factor (TNF) Receptor Shedding Controls Thresholds of Innate Immune Activation That Balance Opposing TNF Functions in Infectious and Inflammatory Diseases

By Sofia Xanthoulea, Manolis Pasparakis, Stavroula Kousteni, Cord Brakebusch, David Wallach, Jan Bauer, Hans Lassmann and George Kollias

Abstract

Tumor necrosis factor (TNF) is a potent cytokine exerting critical functions in the activation and regulation of immune and inflammatory responses. Due to its pleiotropic activities, the amplitude and duration of TNF function must be tightly regulated. One of the mechanisms that may have evolved to modulate TNF function is the proteolytic cleavage of its cell surface receptors. In humans, mutations affecting shedding of the p55TNF receptor (R) have been linked with the development of the TNFR-associated periodic syndromes, disorders characterized by recurrent fever attacks and localized inflammation. Here we show that knock-in mice expressing a mutated nonsheddable p55TNFR develop Toll-like receptor–dependent innate immune hyperreactivity, which renders their immune system more efficient at controlling intracellular bacterial infections. Notably, gain of function for antibacterial host defenses ensues at the cost of disbalanced inflammatory reactions that lead to pathology. Mutant mice exhibit spontaneous hepatitis, enhanced susceptibility to endotoxic shock, exacerbated TNF-dependent arthritis, and experimental autoimmune encephalomyelitis. These results introduce a new concept for receptor shedding as a mechanism setting up thresholds of cytokine function to balance resistance and susceptibility to disease. Assessment of p55TNFR shedding may thus be of prognostic value in infectious, inflammatory, and autoimmune diseases

Topics: Article
Publisher: The Rockefeller University Press
OAI identifier: oai:pubmedcentral.nih.gov:2211976
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2000). A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling.
    2. (1995). A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor.
    3. (1990). Characterization in vitro of a human tumor necrosis factorbinding protein. A soluble form of a tumor necrosis factor receptor.
    4. (1991). Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific.
    5. (1998). Crucial role of TNF receptor type 1 (p55), but not of TNF receptor type 2 (p75), in murine toxoplasmosis.
    6. (1994). Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice.
    7. (1994). Functional immunoglobulin transgenes guide ordered B-cell differentiation in Rag-1-deficient mice. Genes Dev.
    8. (1986). Germ-line transmission of genes introduced into cultured pluripotential cells by retroviral vector.
    9. (1999). Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes.
    10. (1993). Human TNF mutants with selective activity on the p55 receptor.
    11. (1996). Immune and inflammatory responses in TNF –deficient mice: a critical requirement for TNF in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response.
    12. (2003). INFEVERS: the registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res.
    13. (1990). Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans.
    14. (1995). Inhibition of the release of soluble tumor necrosis factor receptors in experi-Role of TNFR Shedding in Pathophysiology 376 mental endotoxemia by an anti-tumor necrosis factor-alpha antibody.
    15. Lipopolysaccharide LPS-mediated soluble TNF receptor release and TNF receptor expression by monocytes. Role of CD14, LPS binding protein, and bactericidal/permeability-increasing protein.
    16. (1989). Listeriolysin O is essential for virulence of Listeria monocytogenes: direct evidence obtained by gene complementation.
    17. (1993). LPS-induced sTNF-receptor release in vivo in a murine model. Investigation of the role of tumor necrosis factor, IL-1, leukemia inhibiting factor, and IFN-gamma.
    18. (1993). Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection.
    19. (1993). Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes.
    20. (1995). Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75.
    21. (1989). Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells.
    22. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.
    23. (1996). Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers.
    24. (1990). Shedding of tumor necrosis factor receptors by activated human neutrophils.
    25. Slow release of soluble TNF receptors by monocytes in vitro.
    26. (1995). Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis.
    27. (1994). Structural requirements for inducible shedding of the p55 tumor necrosis factor receptor.
    28. (1996). The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev.
    29. (1994). The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death.
    30. (2002). The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine
    31. (1998). TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation.
    32. (1996). TNF receptors in murine Candida albicans infection: evidence for an important role of TNF receptor p55 in antifungal defense.
    33. (2000). TNFRSF1A mutations and autoinflammatory syndromes.
    34. (1991). Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.
    35. (1998). Trypanosoma cruzi infection in tumor necrosis factor receptor p55-deficient mice.
    36. (1999). Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infections.
    37. (2000). Tumor necrosis factor and the p55TNF receptor are required for optimal development of the marginal sinus and for migration of follicular dendritic cell precursors into splenic follicles.
    38. (1999). Tumor necrosis factor receptor and Fas signaling mechanisms.
    39. (2003). Tumor necrosis factor receptor-associated periodic syndrome characterized by a mutation affecting the cleavage site of the receptor: implications for pathogenesis. Arthritis Rheum.
    40. (2003). Tumor necrosis factor signaling. Cell Death Differ.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.